June #48 : Rescue 3-8-7 - by Dave Gilden

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Afterimage

Beyond Condoms: Introduction

Beyond Condoms

Beyond Condoms: Life After Latex

Ouch! Stop the Pain

Catching Up With . . . Jim Howley

Drag King

Queen of Hearts

S.O.S.

To the Editor

Hypodermic Hysteria

Streethearts

POZarazzi: Party Poop

Frogs Out of Hot Water

Clip 'n' Save

Swing Vote

Think Stink

"WeHo" Heave Ho

Little Rocked

Say What

Obits

Patriot Games

Policy Permutations

Ghost Reader

Show & Tell

Rescue 3-8-7

Dose Encounters

Nurse a Grudge

A Bum Rap

Where There’s Smoke...

Feelin' No Pain

Tranny Time

Where to Find It

Get Over It

Volunteers Wanted

Not Your Typical Tearjerker

Displace Dysplasia

Prevention Extension

Posterboy Always Rings Twice

Sense and Sinsemilla

POZ Picks

Aunt Evelyn's Letters



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 1999

Rescue 3-8-7

by Dave Gilden

PWAs need salvage therapy, and Abbott’s new protease fits the bill. If only?

People with HIV have little to fall back on when therapy fails. Because HIV easily develops cross-resistance to all drugs within a class, each person really has only four effective anti-HIV drugs—two nucleoside analogs, one NNRTI and one protease inhibitor—before their virus becomes resistant to all. For the first time, though, several protease inhibitors in the pipeline show potential for evading cross-resistance. By far the most advanced is Abbott Laboratories’ ABT-378.

In devising ABT-378, Abbott selected a very sticky molecular structure that adheres to its target site on the HIV protease, even in the presence of mutations that defeat other protease inhibitors. And ABT-378 is less likely to stick to blood proteins, a problem that blocks other protease inhibitors from entering cells. Another trick is to combine ABT-378 with small amounts of Abbott’s other protease, ritonavir (Norvir), which reduces the rate at which the liver metabolizes ABT-378. The result is a product relatively easy to take—three capsules twice a day.

These qualities suggest that ABT-378 has an immediate role as a salvage, or rescue, therapy for people doing poorly on other drugs. Abbott first unveiled ABT-378 more than three years ago, and progress has been slow. Last winter, a group of treatment activists (including me) lost patience and decided to pressure Abbott to hurry up, already. We asked the company to expedite testing ABT-378 as a rescue agent and begin planning an expanded access program for people who lack other treatment options. More than 100 organizations and individuals endorsed a consensus statement by the Coalition for Salvage Therapy.

But Abbott insists on going slow. Eugene Sun, head of the firm’s Antiviral Venture, says: “We can’t release this drug on top of the other useless drugs people are taking. If we do things with haste, ABT-378 will be as useless as all the other drugs on expanded access.” ABT-378 is not so unconventional: Like all protease inhibitors, it needs the support of other drugs to suppress the virus’ evolutionary response to therapy.

Abbott now has a single ongoing study of ABT-378 as a second-line therapy cautiously designed to meet the company’s concerns. The trial includes 70 people whose first protease inhibitor proved unable to control their virus and who previously tried no NNRTIs. They take ABT-378 along with the NNRTI Viramune and two nucleoside analogs, at least one of which must be new. Their median viral load at the start was only 10,000, and most dropped rapidly to undetectable levels and stayed there. A preliminary study in people more protease experienced is due this spring.

Meantime, more and more people are in dire straits, burning through treatment options and getting sick. “I have had probably seven deaths in the last year among this group of patients,” says Colin Kovacs, MD, a Toronto HIV specialist with some 450 patients. To help those who are failing, he proposed over a year ago a trial combining ABT-378 with other experimental agents. Abbott rejected this plan as premature.

The Coalition for Salvage Therapy has resurrected Kovacs’ proposal and has also begun building bridges between Abbott and other drug firms. Twenty-person pilot studies of ABT-378 with T-20 or PMPA (two other unapproved candidates for rescue therapy) should be up and running by early next year.

For all those who cannot enter these trials, Abbott officials pledged at a March community meeting to begin an expanded-access program by 2000. But the specifics remain nebulous, and many people cannot afford to wait for Abbott’s deliberations. As they use up drugs to fight the fast-changing virus, they run out of effective drugs to combine with ABT-378. By 2000, their viral loads, their cell counts and perhaps even their physical condition will have worsened, making successful treatment still less likely. New Yorker Fred Labow is already approaching the point of no return. “I’ve gone through everything, and nothing works anymore,” he says. “I’m sitting here with 10 T-cells waiting for new drugs that aren’t coming.” 



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    slimcuteguy
    Asheville
    North Carolina


    OahuAJ
    Turlock
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.